This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q44.2 (biliary atresia) | Special Copayment Reduction: V181 |
| B. Synonyms | Atresia of bile ducts |
| C. Adult onset | Possibility of first onset in adulthood very low — biliary atresia is a congenital/perinatal disease that presents in the neonatal period (within 2–8 weeks of birth) with persistent jaundice, pale gray stools, and dark urine. Without treatment, cirrhosis progresses during infancy, and no one survives to adulthood without treatment. |
| 1. History | 1892 first description by Thomson → 1959 Kasai develops hepatic portoenterostomy (Kasai portoenterostomy) → 1963 Starzl pediatric liver transplantation → modern treatment strategy established. |
| 2. Causes | Abnormal bile duct development + immune/inflammation-mediated bile duct destruction; viral infection (CMV, rotavirus) hypothesis; combined genetic and environmental factors. |
| 3. Genetics | Mostly sporadic; associated with left–right determination genes such as INVS, CFC1, ADD3 (biliary atresia splenic malformation syndrome); ADD3 signal on GWAS. |
| 4. General epidemiology | 1 in 8,000–18,000 births; high frequency in Asia-Pacific; slightly more common in girls; the most common indication for pediatric liver transplantation. |
| 5. Pathophysiology | Bile duct epithelial injury (virus, toxin, autoimmunity) → fibroinflammatory response → bile duct obstruction → reduced bile secretion → liver fibrosis and cirrhosis. |
| 6. Symptoms | Persistent jaundice at 2–8 weeks of age, pale gray stools (acholic stools), dark urine, abdominal distension, hepatomegaly; symptoms of liver failure as it progresses. |
| 7. Signs | Jaundice, hepatomegaly, splenomegaly, ascites, abdominal distension; elevated serum direct bilirubin, elevated GGT; signs of cirrhosis. |
| 8. Screening | Stool color card screening; neonatal direct bilirubin testing; abdominal ultrasound. |
| 9. Diagnosis | Abdominal ultrasound (triangular cord sign), nuclear medicine hepatobiliary scan (HIDA), liver biopsy, intraoperative cholangiography (confirmation). |
| 10. Treatment | Kasai portoenterostomy (optimally performed before 60 days of age); later liver transplantation. |
| 11. Prognosis | Whether bile flow is restored after Kasai is the greatest prognostic factor; native liver retained to age 10 in about 40–50%; most eventually need liver transplantation. |
| 12. Prevention | Primary prevention difficult; early diagnosis through neonatal stool color screening; early performance of the Kasai operation is key. |
| 13. References | Kasai M, 1959; Bezerra JA et al., J Clin Invest 2002; Chardot C, Orphanet J Rare Dis 2006 and 7 others |
Biliary atresia (BA) is a congenital/perinatal disease of the neonatal and infant period in which the extrahepatic bile ducts are replaced by fibrous tissue and bile flow is completely blocked, and it is the most common indication for liver transplantation in children. The first clear clinical description of this disease was made in 1892 by John Thomson of the UK. Thomson described, from pathological anatomy, absent or fibrosed extrahepatic bile ducts in infants who had died, and named this 'congenital obliteration of the bile ducts'.
In the early to mid-20th century, biliary atresia was regarded as an untreatable fatal disease, and even when surgery was attempted, biliary reconstruction was impossible in most cases. The fundamental turning point in treatment was the hepatic portoenterostomy (Kasai portoenterostomy) devised in 1959 by the Japanese pediatric surgeon Morio Kasai. Kasai developed a method of excising the fibrous remnant of the obliterated bile ducts at the porta hepatis and anastomosing a Roux-en-Y loop of small intestine directly to the porta, inducing bile flow through microscopic bile ducts. This operation is regarded as a revolution in the treatment of biliary atresia and became the standard treatment for decades thereafter.
In 1963, Thomas Starzl of the US performed the first pediatric liver transplantation, and after the first successful pediatric liver transplant with long-term survival in 1967, liver transplantation was established as the definitive treatment for biliary atresia. In the 1980s, advances in immunosuppressants such as cyclosporine and in living-donor liver transplantation techniques greatly improved the outcomes of pediatric liver transplantation. In particular, living-donor liver transplantation has become a major treatment for biliary atresia in Asia, including Korea, where deceased donors are scarce.
In Korea, the history of biliary atresia began with the introduction of the Kasai operation in the 1970s, and with the establishment of living-donor liver transplantation techniques in the 1980s–1990s, the survival of children with biliary atresia improved greatly. Currently, patients with biliary atresia in Korea are registered and managed under rare disease Special Copayment Reduction V181, and treatment is provided through a multidisciplinary approach at specialized pediatric gastroenterology and liver transplantation centers. Improvement of prognosis through early diagnosis and early Kasai operation is being pursued through the neonatal stool color card program.
Recent research has deepened understanding of the immunopathogenic mechanisms of biliary atresia, and research on new therapies targeting the regulation of immune-inflammatory responses and fibrosis pathways that begin with bile duct epithelial injury is under way. To improve the results of the Kasai operation, laparoscopic (minimally invasive) Kasai surgery, postoperative immunosuppressive (steroid) adjuvant therapy, and bile acid supplementation (ursodeoxycholic acid) are currently used in combination in clinical practice.
The cause of biliary atresia has not yet been fully elucidated, and two pathogenic concepts coexist: congenital abnormal bile duct development and immune/inflammation-mediated bile duct destruction in the perinatal and early postnatal period. Biliary atresia is currently understood not as a disease with a single uniform cause but as the final common phenotype of various etiologies.
Abnormal bile duct development hypothesis: some cases of biliary atresia (about 10–15%) take the form of biliary atresia splenic malformation (BASM), accompanied by left–right determination abnormalities such as splenic malformations, situs inversus, and polysplenia, and in these cases abnormal bile duct development in early fetal life is presumed to be the cause. In the BASM form, variants in left–right determination genes such as CFC1, INVS, and ZIC3 have been reported in some cases.
Viral infection hypothesis: most biliary atresia (about 85–90%) is non-syndromic (isolated BA), understood as normally developed bile ducts being damaged by viral infection or the like in the perinatal or early postnatal period, with secondary progression of bile duct destruction and fibrosis due to immune and inflammatory responses. Viruses that have been proposed include cytomegalovirus (CMV), rotavirus, reovirus, Epstein-Barr virus (EBV), and hepatitis B virus (HBV). In particular, animal experiments confirmed that administering rotavirus to newborn mice produces biliary atresia-like lesions, so rotavirus is supported as an important pathogenic hypothesis.
Autoimmunity/immune dysregulation hypothesis: excessive activation of T lymphocytes, reduction of regulatory T cells (Treg), and autoantibodies against bile duct epithelium have been reported in biliary atresia lesion tissue, raising the possibility of an autoimmune mechanism. TH1 immune responses and overactivation of profibrotic cytokines (TGF-β, TNF-α, IL-6, IL-8) are involved in bile duct fibrosis.
Toxin/environment hypothesis: it has also been hypothesized that bile acid toxicity and exposure to certain toxins during pregnancy (plant-derived substances such as isothiocyanates) are associated with the development of biliary atresia. Seasonal clustering of cases has been reported in some regions, also suggesting involvement of environmental factors. However, no single environmental cause has been established.
The genetic basis of biliary atresia is complex, and most cases occur sporadically. Familial biliary atresia is rare (less than about 2% of all cases), suggesting the involvement of complex genetics or gene–environment interactions rather than simple Mendelian inheritance.
Biliary atresia splenic malformation (BASM): in this form, variants in genes that regulate left–right determination are involved. Variants in genes such as CFC1 (cryptic, left-right axis determination), INVS (inversin), ZIC3, and PKD2 have been reported. Heterotaxy-related genes share overlapping pathogenesis with BASM.
Genome-wide association study (GWAS): a large biliary atresia GWAS (Chung et al., 2017) first reported that variants at the ADD3 (adducin 3) gene locus (10q24.2) are associated with biliary atresia risk. ADD3 is a cytoskeletal protein involved in the polarity and function of bile duct epithelial cells. This association has since been replicated in several East Asian cohorts.
Immune regulatory genes: GWAS and candidate gene studies have reported that polymorphisms in immune response-related genes such as IL-8, MIF (macrophage migration inhibitory factor), and STAT3 are associated with the development of biliary atresia or outcomes after the Kasai operation. There are also studies reporting that particular combinations of HLA types are associated with biliary atresia risk, but there are no consistent results yet.
Fibrosis-related genes: there are studies suggesting that variants in TGF-β signaling pathway genes (TGFB1, SMAD3) and liver fibrosis-related genes (COL1A1, COL4A1) may be associated with the rate of fibrosis progression after the Kasai operation. Rapid progression of liver fibrosis has an important effect on the duration of native liver survival after Kasai. Routine genetic testing of patients with biliary atresia is currently not recommended in clinical practice, but genetic counseling and chromosomal analysis may be helpful in the BASM form.
Biliary atresia is a rare disease occurring worldwide at a frequency of about 1 in 8,000–18,000 births. Regional differences in prevalence are marked, with a higher frequency of about 1 in 5,000–10,000 reported in the Asia-Pacific region (especially Taiwan, Hong Kong, Japan, Korea, China) than in Western countries (about 1 in 10,000–15,000). The cause of this difference has not yet been clearly established, but genetic predisposition, environmental factors (viral exposure, diet), or reporting bias may be involved.
Reports consistently show that it is slightly more common in girls, at a ratio of about 1.1–1.5:1. Apart from the higher prevalence in people of Asian descent, there is no clear ethnic specificity. Biliary atresia occurs either alone (isolated type, about 85–90%) or accompanied by other congenital malformations such as splenic malformations (BASM type, about 10–15%). The BASM form is reported to have poorer outcomes after the Kasai operation than the isolated form.
Epidemiology in Korea: in Korea, biliary atresia occurs in about 1 in 8,000–12,000 births and is registered and managed under Special Copayment Reduction V181. It is the most common indication for pediatric liver transplantation in Korea, accounting for about 50–60% of all pediatric liver transplants. The median age at Kasai operation in Korea is about 55–65 days, and efforts to increase the proportion performed early (before 60 days of age) are ongoing. The neonatal stool color card program has been implemented in some regions, improving the rate of early diagnosis.
Biliary atresia is the most common single cause of chronic liver disease in childhood and of pediatric liver transplantation, accounting for about 40–70% of pediatric liver transplants worldwide. About 40–50% of patients who undergo the Kasai operation retain their native liver until age 10, but eventually 70–80% need liver transplantation before adulthood. With advances in modern liver transplantation, 20-year survival of patients with biliary atresia reaches 85–90%, and a normal life is possible after transplantation.
The key to the pathogenesis of biliary atresia is a vicious cycle of immunity, inflammation, and fibrosis that begins with bile duct epithelial injury.
Initial injury: bile duct epithelial cells are damaged by viruses, toxins, or developmental abnormalities. Damaged bile duct epithelium releases damage-associated molecular patterns (DAMPs) and activates innate immune responses. Natural killer cells (NK cells), dendritic cells, and macrophages are activated, infiltrate around the bile ducts, and amplify the inflammatory response.
Immune-mediated bile duct destruction: activated CD4+ T cells (TH1-biased) secrete interferon-gamma (IFN-γ) and TNF-α, further damaging bile duct epithelial cells. CD8+ cytotoxic T cells also directly destroy bile duct epithelium. Reduced function of regulatory T cells (Treg) impairs immune tolerance and promotes autoimmune bile duct destruction. Cytokines such as IL-6, IL-8, and TGF-β are oversecreted and promote fibrosis.
Bile duct fibrosis and obstruction: with repeated inflammatory responses and loss of bile duct epithelium, the bile ducts are replaced by fibrous tissue. Hepatic stellate cells are activated (TGF-β stimulation), overproduce collagen, and liver fibrosis progresses. When bile stagnates in the liver owing to bile duct obstruction, bile acid toxicity accelerates hepatocyte injury.
Progression to cirrhosis: progresses along the path of reduced bile secretion (cholestasis) → bile acid toxicity → hepatocyte necrosis → liver fibrosis → cirrhosis → portal hypertension → esophageal varices, ascites, hepatic encephalopathy, and liver failure. Without treatment, severe liver failure develops in most within 6–12 months of birth.
Even when the Kasai operation succeeds and bile flow is restored, the intrahepatic fibrotic process that has already begun often does not stop completely, so gradual progression of cirrhosis occurs in most patients. Therefore, biliary atresia is a progressive disease that is rarely cured permanently without liver transplantation, even when bile flow is restored by the Kasai operation.
The clinical symptoms of biliary atresia center on the characteristic triad of the neonatal and infant period (jaundice, pale gray stools, dark urine) caused by complete blockage of bile flow.
Jaundice: in most newborns with biliary atresia, jaundice persists or worsens even at the age when normal physiological jaundice disappears (2–3 weeks of age). Jaundice in biliary atresia is mainly due to elevated direct (conjugated) bilirubin, and the skin and sclera are deep yellow. Unlike physiological jaundice, a direct bilirubin fraction of 20% or more of total bilirubin strongly suggests cholestasis.
Pale gray stools (acholic stool): because bile is not excreted into the intestine, the stool lacks the bile pigment (stercobilin) that gives it its normal yellow to brown color, so it is pale gray or light yellowish-brown. Pale gray stools are a very specific symptom of biliary atresia, and recognizing them early is key to rapid diagnosis. In Korea, early screening using a neonatal stool color card (color chart) is being carried out in some places.
Dark urine: when bile cannot be excreted into the intestine, refluxes into the blood, and is excreted through the kidneys, the urine becomes dark brown or tea-colored. This is a result of direct hyperbilirubinemia.
Abdominal distension and hepatomegaly: owing to intrahepatic cholestasis and progressive liver fibrosis, the liver becomes enlarged (hepatomegaly) and hard. The abdomen becomes distended, and the spleen also enlarges when portal hypertension develops.
Symptoms of progressive liver failure: without treatment or when the Kasai operation fails, ascites, esophageal and gastric variceal bleeding, spontaneous bacterial peritonitis, hepatic encephalopathy, coagulopathy (bleeding), hypoalbuminemia, growth failure, fatigue, and itching (bile acid deposition in the skin) appear within 6–12 months of birth, progressing to liver failure.
The physical and laboratory signs are as follows.
Jaundice: yellow discoloration of the skin and sclera is distinct. Skin itching (pruritus) due to bile acid deposition is sometimes present.
Hepatomegaly: the liver is palpably firm, and obvious liver enlargement is found in the right upper quadrant or epigastrium. Initially the liver is soft and enlarged, but it becomes hard as fibrosis progresses.
Splenomegaly: when portal hypertension develops, the spleen enlarges to become palpable. Thrombocytopenia due to hypersplenism may be present.
Ascites: ascites develops as cirrhosis and hypoalbuminemia progress. Shifting dullness and a fluid wave are found.
Laboratory findings: markedly elevated direct (conjugated) bilirubin (50% or more of total bilirubin, absolute value 2 mg/dL or more), elevated gamma-GT (GGT) (particularly prominent in biliary atresia), elevated alkaline phosphatase (ALP), and elevated serum total bile acids are characteristic. ALT and AST are moderately elevated. As it progresses, prolonged PT, low albumin, and thrombocytopenia appear. Elevated serum GGT is useful for differentiating biliary atresia from neonatal hepatitis (GGT is markedly high in biliary atresia).
Abdominal ultrasound findings: it is characteristic that the extrahepatic bile ducts are not seen (the gallbladder is absent or small) and that a triangular cord sign (TC sign) is observed at the porta hepatis. The TC sign is fibrotic tissue at the porta hepatis appearing as a right-triangular or triangular echogenic structure, with a sensitivity of about 73–85% and specificity of about 98% for biliary atresia.
Because early diagnosis of biliary atresia is directly linked to the success rate of the Kasai operation, effective screening methods are clinically very important.
Infant Stool Color Card: this screening method, which began in Taiwan, gives parents of newborns a card containing a color chart of pale gray stools, and caregivers judge whether there is an abnormality based on stool color. A large study in Taiwan reported that this screening program significantly lowered the age at Kasai operation and improved native liver survival. In Korea, it is being piloted in some regions, and nationwide expansion is under discussion.
Neonatal direct bilirubin testing: an approach that includes direct bilirubin measurement in the newborn screening blood test, with additional tests to evaluate the cause of cholestasis performed when direct bilirubin is elevated. Inclusion in the newborn screening panel is being considered in some US states.
Systematic evaluation of newborns with persistent jaundice: in all newborns with jaundice persisting beyond 2 weeks of age, the direct bilirubin fraction should be checked, and when direct bilirubin is elevated (20% or more of total bilirubin or 2 mg/dL or more), evaluation of the causes of cholestasis, including biliary atresia, should be carried out immediately. Speeding up the diagnostic process is very important so that the Kasai operation can be performed before 60 days of age whenever possible.
Biliary atresia is diagnosed through a stepwise approach, and final confirmation is made by intraoperative cholangiography.
Abdominal ultrasound: as the first-line noninvasive test, it assesses gallbladder size and shape (small, absent, or not contracting), the presence of extrahepatic bile ducts, the triangular cord sign, hepatic parenchymal echogenicity, and spleen size. A gallbladder that is absent or very small (less than 1.5 cm) and does not contract even after feeding, together with a TC sign, strongly suggests biliary atresia.
Nuclear medicine hepatobiliary scan (HIDA scan): measures whether a radioisotope secreted by the liver (Tc-99m DISIDA, etc.) is excreted into the small intestine through normal bile ducts. In biliary atresia, the radioisotope is not excreted into the intestine. Before the test, pretreatment with phenobarbital for 5 days maximizes hepatic secretory function. With a sensitivity of about 100% and specificity of about 70–80%, false negatives are rare, but false positives (non-excretion also in neonatal hepatitis) occur.
Liver biopsy: ductular proliferation, bile plugs, fibrosis of the portal tracts, and cholestatic findings are characteristic findings of biliary atresia. It helps in differentiation from neonatal hepatitis, but confirmation by histological findings alone is difficult.
Intraoperative cholangiography: the confirmatory method for biliary atresia. Contrast medium is injected into the gallbladder or residual bile duct to visualize the bile duct structure, and biliary atresia is confirmed if the intrahepatic bile ducts are not seen (or the extrahepatic bile ducts are blocked without continuity). The Kasai operation can be performed immediately at this point. Preoperative magnetic resonance cholangiopancreatography (MRCP) is sometimes used as a diagnostic aid.
Treatment of biliary atresia consists of two stages, the Kasai operation and liver transplantation, and a multidisciplinary approach is essential.
Kasai portoenterostomy: an operation that widely excises the fibrotic bile duct remnant at the porta hepatis and anastomoses a Roux-en-Y small intestinal loop to the porta to promote bile drainage from microscopic intrahepatic bile ducts. The key factor in surgical success is age at operation, and the likelihood of restoring bile flow (achieving normal bilirubin) is highest when it is performed before 60 days of age. When performed after 60 days of age, the success rate is significantly lower. There is evidence that postoperative steroid (prednisolone) administration helps improve bile flow and prevent infection, but standard protocols vary by institution. Ursodeoxycholic acid (UDCA) is given long term to reduce bile acid toxicity.
Postoperative management: prevention and treatment of cholangitis is an important management task after the Kasai operation. Cholangitis results from reduced bile flow and retrograde infection by intestinal bacteria and presents with fever, worsening jaundice, and abdominal pain. Prophylactic antibiotics (trimethoprim-sulfamethoxazole, ampicillin, etc.) are used for prevention. Nutritional support (high-calorie diet, fat-soluble vitamin supplementation) is important for growth and maintenance of liver function.
Liver transplantation: liver transplantation is needed when the Kasai operation fails (bile flow cannot be restored) or when progressive cirrhosis develops after surgery. In Asia, including Korea, because of the shortage of deceased donors, living-donor liver transplantation (LDLT) is performed as the standard treatment. The left lateral segment of the liver is transplanted from a suitable donor among parents, siblings, or family. After transplantation, immunosuppressants (tacrolimus-based calcineurin inhibitors) must be taken for life. One-year survival after transplantation is over 90%, and 10-year survival reaches 85–90%.
The prognosis of biliary atresia varies greatly according to age at the Kasai operation, whether bile flow is restored, the rate of progression of liver fibrosis, and the frequency of cholangitis.
Results after the Kasai operation: in patients who undergo the Kasai operation before 60 days of age, bile flow is restored (normal bilirubin achieved) in about 50–80%. Of the patients whose bile flow is restored, about 40–50% retain their native liver without liver transplantation until age 10. When restoration of bile flow fails, most need liver transplantation before age 2. When surgery is performed after 90 days of age, the rate of restoration of bile flow is markedly lower.
Long-term prognosis: even most patients with native liver survival often progress to cirrhosis in adulthood and need liver transplantation. Some studies report native liver survival of 40–50% at 10 years and 30–40% at 20 years. Current data show 20-year overall survival after diagnosis of biliary atresia (including native liver + transplantation) of 85–90% or more, owing largely to advances in liver transplantation.
Prognosis after transplantation: with successful liver transplantation, normal growth and development and social participation are possible. Ongoing monitoring for long-term adverse effects of immunosuppressants (renal toxicity, susceptibility to infection, increased risk of malignancy) is needed. Post-transplant biliary complications (bile duct stricture, bile leak), vascular complications (hepatic artery thrombosis), and graft rejection are the main complications.
Primary prevention of biliary atresia (preventing the disease itself) is currently difficult because its cause has not been fully elucidated. Based on the hypothesis that rotavirus infection is involved in its pathogenesis, it has been hypothesized that rotavirus vaccination may have a potential preventive effect, but this has not yet been clinically confirmed.
Secondary prevention — early diagnosis: the most reliable way to improve the prognosis of biliary atresia is early diagnosis. The most important preventive strategy is the introduction of a systematic screening program that detects pale gray stools early through the neonatal stool color card, immediately checks the direct bilirubin fraction in newborns with jaundice persisting beyond 2 weeks of age, and ensures that the Kasai operation is performed before 60 days of age. Experience with successful screening programs in Taiwan, Japan, and elsewhere is providing the basis for expanding the program nationwide in Korea as well.
Tertiary prevention — prevention of complications: prevention of cholangitis after the Kasai operation (prophylactic antibiotics, immediate treatment of infections), nutritional support (fat-soluble vitamin supplementation, adequate calorie supply), monitoring of liver fibrosis progression (regular liver function tests, ultrasound), and early treatment of complications of portal hypertension (esophageal varices, ascites) contribute to extending native liver survival. After liver transplantation, regular follow-up for graft rejection and adverse effects of immunosuppressants is essential.